Therapeutic strategies for BC are defined according to the immunohistochemical detection of tumor biomarkers which include estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (HER2), and Ki67 (Harbeck et al. 2019). This evidence concerns the gene ERBB2 and breast cancer.